Devyser Inc.
Devyser is a pioneer in diagnostic kits and solutions for advanced DNA testing, aiming to make personalized healthcare accessible through fast, accurate, and easy-to-use genetic testing solutions. Founded in 2004 in Stockholm, Sweden, the company develops innovative products that streamline laboratory workflows and improve patient outcomes. With a global presence in over 50 countries, Devyser is committed to innovation, simplicity, relevance, and empathy in genetic diagnostics.
Industries
Nr. of Employees
medium (51-250)
Patents
Selective amplification of desired nucleic acid regions in a target sequence
US-10246740-B2
View Details
Selective amplification of desired nucleic acid regions in a target sequence
US-10246740-B2
View DetailsProducts
Targeted NGS assay panels for clinical diagnostics
A portfolio of targeted amplicon NGS assay panels for applications including thalassemia, cystic fibrosis (CFTR), hereditary cancer, chimerism, donor-derived cfDNA monitoring, fetal RHD screening and genomic blood typing.
Regulated NGS analysis software (diagnostic-grade pipelines)
Diagnostic-grade software for NGS data analysis that includes certified pipelines for specified panels and research-use-only pipelines for others.
Post-transplant monitoring software
Specialized software for longitudinal analysis and reporting of transplant monitoring assays, including timelines and clinical visualization for chimerism and donor-derived cfDNA.
Targeted NGS assay panels for clinical diagnostics
A portfolio of targeted amplicon NGS assay panels for applications including thalassemia, cystic fibrosis (CFTR), hereditary cancer, chimerism, donor-derived cfDNA monitoring, fetal RHD screening and genomic blood typing.
Regulated NGS analysis software (diagnostic-grade pipelines)
Diagnostic-grade software for NGS data analysis that includes certified pipelines for specified panels and research-use-only pipelines for others.
Post-transplant monitoring software
Specialized software for longitudinal analysis and reporting of transplant monitoring assays, including timelines and clinical visualization for chimerism and donor-derived cfDNA.
Services
Diagnostic testing and reporting services performed in an accredited clinical laboratory environment.
Operational and technical support, including hands-on and online training for assay implementation and bioinformatics use.
Deployment and hosting of regulated NGS analysis software with options for cloud hosting or secure local installation.
Diagnostic testing and reporting services performed in an accredited clinical laboratory environment.
Operational and technical support, including hands-on and online training for assay implementation and bioinformatics use.
Deployment and hosting of regulated NGS analysis software with options for cloud hosting or secure local installation.
Expertise Areas
- NGS-based diagnostic assay development
- Post-transplant monitoring and chimerism analysis
- Chimerism assay design using population-independent marker panels
- Clinical bioinformatics and variant interpretation
Key Technologies
- Next-generation sequencing (targeted amplicon NGS)
- Variant calling and annotation (SNV/indel/CNV)
- Donor-derived cell-free DNA quantification by NGS
- Chimerism measurement by NGS
News & Updates
Devyser hosted its first Capital Markets Day, sharing insights from management and stakeholders.
Devyser announced the global launch of a comprehensive blood typing assay based on NGS.
Devyser announced the launch of a high-precision NGS assay for HLA loss detection.
Devyser was awarded a significant contract for genetic testing solutions in Italy.
Devyser Genomic Laboratories received CAP accreditation.
Devyser's NGS products for transplant monitoring have received IVDR approval.
Devyser hosted its first Capital Markets Day, sharing insights from management and stakeholders.
Devyser announced the global launch of a comprehensive blood typing assay based on NGS.
Devyser announced the launch of a high-precision NGS assay for HLA loss detection.
Devyser was awarded a significant contract for genetic testing solutions in Italy.
Devyser Genomic Laboratories received CAP accreditation.
Devyser's NGS products for transplant monitoring have received IVDR approval.